Foley Hoag LLP represented Satellite Bio, a regenerative medicine company, in raising $110 million in Seed and Series A funding. The recent Series A round was led by aMoon Growth with participation from prior Seed stage investors. The funds will be used to support the development of bioengineered tissues that repair, restore or replace critical organ or tissue function.
Satellite Bio is on a journey to treat some of the most elusive diseases known to humankind by pioneering Tissue Therapeutics, an entirely new category of regenerative medicine. With the first-of-its-kind SAT (Satellite Adaptive Tissues) platform, Satellite Bio can turn virtually any cell type into bioengineered tissues that are integrated into the body to restore natural function. The SAT platform is an unprecedented technology with the potential to drive a pipeline of sophisticated cell-based therapeutic solutions that tackle a broad range of elusive diseases.
Foley Hoag attorneys Jeff Quillen, Brendan Burke, Jason Roche and Ivanna Bihun represented Satellite Bio in the funding round.